
CLAIMS

1. A thienopyridone derivative of Formula (I):



(I)

wherein:

R1 represents a hydrogen atom or a halogen atom,

R2 represents an indanyl or tetralinyl group, substituted or not by one or more groups selected from halogen atoms, alkyl groups, hydroxy, alkoxy groups, amino, mono- or di-alkylamino groups, carboxy groups, alkyloxycarbonyl groups, mono- or di-alkylaminocarbonyl groups, carboxamide, cyano, alkylsulfonyl and trifluoromethyl groups,

R3 represents an aryl group, substituted or not by one or more atoms or groups selected from halogen atoms, alkyl groups, hydroxy, alkoxy groups, aralkyloxy groups, amino, mono- or di-alkylamino groups, carboxy groups, alkyloxycarbonyl groups, mono- or di-alkylaminocarbonyl groups, carboxamide, cyano, alkylsulfonyl and trifluoromethyl groups,

or its pharmaceutically acceptable salts and/or solvates,

or a pharmaceutical composition comprising the same,

for use in the treatment of autosomal dominant polycystic kidney disease (ADPKD).

2. The thienopyridone derivative of claim 1 or a pharmaceutical composition comprising the same for use according to claim 1, wherein said compound is administered once or twice a day at a daily dose of 0.5mg to 3000 mg for a human patient, preferably from 20 mg to 1000 mg, more preferably from 60 mg to 500 mg.

3. The thienopyridone derivative of claim 1 or a pharmaceutical composition comprising the same for use according to claim 1 or 2, wherein said compound or pharmaceutical composition is effective for preventing or limiting cyst growth or reducing cyst volume.


4. The thienopyridone derivative of claim 1 for use according to any one of claims 1 to 3, wherein at least one of the following conditions is met and preferably all of them:

- R1 represents a halogen atom, in particular a chlorine atom,
- R2 is unsubstituted or substituted by 1 or 2 substituents including at least one hydroxy group,
- R2 is a tetralinyl group,
- R3 represents a phenyl group, which is unsubstituted or substituted by 1 or 2 substituents,
- the compound of formula (I) is in the form of a salt, preferably a sodium or potassium salt, more preferably a potassium salt,
- the compound of formula (I) is in the form of a solvate, preferably a hydrate, more preferably a monohydrate.

5. The thienopyridone derivative of claim 4 for use according to any one of claims 1 to 3, wherein at least one of the following conditions is met and preferably all of them:

- R1 represents a halogen atom, in particular a chlorine atom,
- R2 is substituted by 1 or 2 substituents including at least one hydroxy group,
- R2 is a tetralinyl group,
- R3 represents a phenyl group, which is unsubstituted,
- the compound of formula (I) is in the form of a salt, preferably a sodium or potassium salt, more preferably a potassium salt,
- the compound of formula (I) is in the form of a solvate, preferably a hydrate, more preferably a monohydrate.

6. The thienopyridone derivative of claim 5 for use according to any one of claims 1 to 3 which is the monohydrate potassium salt of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one having Formula (Ia):




(Ia)

7. The thienopyridone derivative of claim 1 for use according to any one of claims 1 to 3, wherein at least one of the following conditions is met and preferably all of them:


- R1 represents a halogen atom, in particular a chlorine atom,
- R2 is substituted by 1 or 2 substituents including at least one hydroxy group,
- R2 is an indanyl group,
- R3 represents a phenyl group, which is unsubstituted or substituted by 1 or 2 substituents.

8. The thienopyridone derivative of claim 7 for use according to any one of claims 1 to 3 which is the 2-chloro-5-(4-fluorophenyl)-4-hydroxy-3-indan-5-yl-7H-thieno[2,3-b]pyridin-6-one having Formula (Ib):



(Ib)

9. The thienopyridone derivative of claim 7 for use according to any one of claims 1 to 3 which is the 2-chloro-4-hydroxy-3-indan-5-yl-5-phenyl-7H-thieno[2,3-b]pyridin-6-one having Formula (Ic):



(Ic)